LGVN
Longeveron Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.49
−8.12%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$1.95
- Revenue estimate
- $563.5K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.19
- EPS estimate
- -$0.17
- Revenue actual
- $287.0K
- Revenue estimate
- $326.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -4.6%
- Revenue beats (12Q)
- 4
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.17 | -$0.19 | Miss -8.57% | $287.0K |
| May 13, 2026 | -$0.19 | -$0.19 | In line | $398.0K |
| Mar 17, 2026 | -$0.37 | -$0.22 | Beat 40.00% | $365.0K |
| Nov 4, 2025 | -$0.26 | -$0.39 | Miss -50.00% | $137.0K |
| Aug 13, 2025 | -$0.35 | -$0.33 | Beat 5.71% | $316.0K |
| May 8, 2025 | -$0.34 | -$0.34 | In line | $381.0K |
| Feb 28, 2025 | -$0.36 | -$2.50 | Miss -594.44% | $603.0K |
| Aug 14, 2024 | -$1.03 | -$1.83 | Miss -77.67% | $468.0K |
| Feb 27, 2024 | -$2.10 | -$2.50 | Miss -19.05% | $63.0K |
| Nov 10, 2023 | -$2.40 | -$2.80 | Miss -16.67% | $150.0K |
| Aug 11, 2023 | -$2.60 | -$2.70 | Miss -3.85% | $217.0K |
| May 12, 2023 | -$1.90 | -$2.20 | Miss -15.79% | $279.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026